ClinicalTrials.gg
CompletedNCT00493311Updated Oct 19, 2016Results posted

Safety of Intravenous Acetaminophen Vs Placebo for the Treatment of Endotoxin-Induced Fever in Healthy Adult Males

A Phase 3 interventional study of IV Placebo and IV Acetaminophen in Fever, sponsored by Mallinckrodt. Completed at 1 site in United States. Open to male participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-10-19.

Sponsored by Mallinckrodt · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 31 studies testing acetaminophen in Fever — 1 open to participants now, 1 under way, none of them phase 3. Acetaminophen · Fever.

Enrollment
20th of 31
60 · median 100
Started
2007
with 4 others
Phase 3
8 of 31
none open now
Registered
6th of 31
by date
Lead sponsor
5 of 31
Mallinckrodt

Among the 31 studies testing acetaminophen in Fever, this one is the 20th largest by enrollment, is one of 5 that started in 2007, is one of 8 in phase 3, and was the 6th registered.

Fever

438 studies on the registry are indexed under Fever; 55 are open to participants now.

Browse Fever studies →

Open to participants now

1 of the 31 studies testing acetaminophen in Fever is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About acetaminophen

Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 38 Fever studies recruiting now, 18 (47%) set no upper age limit and 14 (37%) stop at 75 or younger; 22 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing acetaminophen in Fever, or all of them as a file.
02

Study summary

A research study to determine if acetaminophen (APAP) given intravenously (IV-a liquid given through a needle into a vein in your arm) is safe and effective in controlling fever when compared to placebo. Acetaminophen given this way is the investigational part of this study.

Read the detailed description

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Study of the Efficacy and Safety of Intravenous Acetaminophen (IVAPAP) Versus Placebo for the Treatment of Endotoxin-Induced Fever in Healthy Adult Males

03

Conditions studied

  • Fever

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provide written prior to participation in the Study
  • Be a healthy male between the ages of 18 and 75 years of age, inclusive, at Randomization
  • Have a (BMI) ≥ 19 and ≤ 40 lbs / in2
  • Have the ability to read and understand the Study procedures and have the ability to communicate meaningfully with the Study Investigator and staff
  • Be free of physical, mental, or medical conditions which, in the opinion of the Investigator, may confound quantifying assessments for the Study
  • Be willing to abstain from smoking cigarettes or using nicotine products from the time of admission to Clinic until Study Completion

Inclusion Criteria (Pre-Randomization) To be eligible for entry into the Study, Subjects must meet each of the following criteria prior to Randomization:

  • Be free of evidence of infection based upon clinical assessment and blood (Complete Blood Count-CBC) and urine testing
  • Have an average baseline oral temperature that is equal to or below 37 ºC (98.6 ºF) and does not vary more than 0.4 ºC (0.7 ºF) from lowest to highest on three assessments performed during a 30 minute period
  • Not develop a medically significant allergic or exaggerated systemic response to administration of a test dose of reference standard endotoxin
  • Develop a core temperature of at least 38.6 ºC (101.5 ºF) after intravenous reference standard endotoxin dosed per Study guidelines and have a fever response to endotoxin that is at or near the peak temperature by virtue of two consecutive temperature assessments 5 minutes apart that are within 0.2 ºC (0.4 ºF) of each other

Exclusion criteria

Exclusion Criteria:

  • Has been treated with any medication having antipyretic effects (e.g., , Non-steroidal anti-inflammatory drug (NSAID), aspirin or acetaminophen) within 2 days of clinic admission (aspirin at low dose for cardiac prophylaxis is allowed, but should not be taken on the day of the Study)
  • Has significant medical disease(s), laboratory abnormalities, or condition(s) that in the Investigator's judgment could compromise the Subject's welfare, ability to communicate with the Study staff, complete Study activities, or would otherwise contraindicate Study participation.
  • Has known or to receiving endotoxin that in the Investigator's clinical judgment merits discontinuation from further Study participation
  • Has known hypersensitivity to acetaminophen, the inactive ingredients () of the Intravenous(IV) acetaminophen formulation or the Rescue Medications (ibuprofen, aspirin and ketorolac)
  • Has known or suspected recent history of alcohol or drug abuse or dependence as defined by , 4th Edition (DSM-IV) criteria
  • Has a history of nasal polyps, angioedema, significant or actively treated bronchospastic disease, or any other significant medical condition that contraindicates participation in the Study or receiving endotoxin, Study Medication, or Rescue Medication
  • Has an active infection or other disease or condition that may cause abnormal alterations in body temperature, or has worked the night shift on a regular basis for the last 3 months prior to Screening
  • Has impaired liver function, e.g. (ALT) greater than or equal to 3 times the , greater than 3.0, active hepatic disease, or evidence of liver disease (e.g., cirrhosis or hepatitis)
  • Has participated in another clinical Study ( or marketed product) within 30 days of Screening
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    IV Acetaminophen

    1 g of acetaminophen in 100 mL of intravenous solution

    Drug: IV Acetaminophen · Biological: Reference Standard Endotoxin (RSE)

  • Placebo comparator
    IV Placebo

    100 mL of intravenous placebo solution

    Drug: IV Placebo · Biological: Reference Standard Endotoxin (RSE)

Interventions

  • DrugIV Placebo

    IV Placebo

    Also known as: Placebo

  • Intravenous acetaminophen solution 1 g / 100 ml

    Also known as: IV APAP, APAP

  • Administration of Reference Standard Endotoxin (RSE) to induce fever. Applicable to both study arms: Administration of a 1 ng/kg body weight test dose of RSE to test for fever response. Observation period of at least 60 minutes to ensure no exaggerated systemic responses, followed by administration of a 4 ng/kg of RSE to induce fever.

    Also known as: IV Acetaminophen, APAP

06

What researchers measure

Primary outcomes

  1. Weighted Sum of Temperature Differences Over 6 Hours (WSTD6) Assessment of the Antipyretic Effect Over 6 h of a Single Dose of IV APAP vs. Placebo for Treatment of Endotoxin-induced Fever

    The primary efficacy endpoint was WSTD6 defined as the weighted sum of temperature differences from the temperature at each assessment timepoint through 6 hours compared with the temperature at T0, weighted by the time elapsed between each 2 consecutive timepoints.

    Time frame: Baseline (T0) to 6 hours post study drug administration

Secondary outcomes

  1. Weighted Sum of Temperature Differences Over 3 Hours (WSTD3) Assessment of the Antipyretic Effect Over 3 Hours of a Single Dose of IV APAP vs. Placebo for Treatment of Endotoxin-induced Fever.

    WSTD3 is defined as the weighted sum of temperature differences from the temperature at each assessment timepoint through the first 3 hours compared with the temperature at T0, weighted by the time elapsed between each 2 consecutive timepoints.

    Time frame: Baseline (T0) to 3 hours

  2. Maximum Temperature Change During the Period From T0 to T360 Minutes (6 Hours After Study Drug Administration)

    Time frame: Baseline (T0) to 360 minutes (6 hours) post study drug administration

  3. The Percentage of Subjects With Temperature Less Than 38 Degrees Celsius at Any Timepoint During the Time From T0 to T360 Minutes (6 Hours After Study Drug Administration)

    Time frame: 360 minutes (6 hours after study drug administration)

  4. Global Assessment of Treatment at T360 Minutes or Early Termination.

    Subject Global Evaluation was assessed by subject using a 4 point categorical scale in response to the following question:Overall, how would you rate the study treatments? 0 = Poor 1. = Fair 2. = Good 3. = Excellent

    Time frame: Baseline (T0) to 6 hours

07

Results

Posted Sep 21, 2010

Participant flow

Subjects were recruited at a single clinical research facility in the United States during July to September 2007.

Participant flow — Overall Study
MilestoneIntravenous (IV) PlaceboIntravenous (IV) Acetaminophen 1 g
Started2931
Completed2729
Not completed22
Withdrew: Need for rescue medication22

Outcome measures

PrimaryWeighted Sum of Temperature Differences Over 6 Hours (WSTD6) Assessment of the Antipyretic Effect Over 6 h of a Single Dose of IV APAP vs. Placebo for Treatment of Endotoxin-induced Fever

The primary efficacy endpoint was WSTD6 defined as the weighted sum of temperature differences from the temperature at each assessment timepoint through 6 hours compared with the temperature at T0, weighted by the time elapsed between each 2 consecutive timepoints.

Time frame:
Baseline (T0) to 6 hours post study drug administration
Reported as:
Mean · Degrees Celsius
Weighted Sum of Temperature Differences Over 6 Hours (WSTD6) Assessment of the Antipyretic Effect Over 6 h of a Single Dose of IV APAP vs. Placebo for Treatment of Endotoxin-induced Fever
Degrees CelsiusIntravenous (IV) PlaceboIntravenous (IV) Acetaminophen 1 g
Weighted Sum of Temperature Differences Over 6 Hours (WSTD6) Assessment of the Antipyretic Effect Over 6 h of a Single Dose of IV APAP vs. Placebo for Treatment of Endotoxin-induced Fever-0.7 ± 3.32-3.7 ± 3.58
SecondaryWeighted Sum of Temperature Differences Over 3 Hours (WSTD3) Assessment of the Antipyretic Effect Over 3 Hours of a Single Dose of IV APAP vs. Placebo for Treatment of Endotoxin-induced Fever.

WSTD3 is defined as the weighted sum of temperature differences from the temperature at each assessment timepoint through the first 3 hours compared with the temperature at T0, weighted by the time elapsed between each 2 consecutive timepoints.

Time frame:
Baseline (T0) to 3 hours
Reported as:
Mean · Degrees Celsius
Weighted Sum of Temperature Differences Over 3 Hours (WSTD3) Assessment of the Antipyretic Effect Over 3 Hours of a Single Dose of IV APAP vs. Placebo for Treatment of Endotoxin-induced Fever.
Degrees CelsiusIntravenous (IV) PlaceboIntravenous (IV) Acetaminophen 1 g
Weighted Sum of Temperature Differences Over 3 Hours (WSTD3) Assessment of the Antipyretic Effect Over 3 Hours of a Single Dose of IV APAP vs. Placebo for Treatment of Endotoxin-induced Fever.0.7 ± 1.36-0.9 ± 1.35
SecondaryMaximum Temperature Change During the Period From T0 to T360 Minutes (6 Hours After Study Drug Administration)
Time frame:
Baseline (T0) to 360 minutes (6 hours) post study drug administration
Reported as:
Mean · Degrees celsius
Maximum Temperature Change During the Period From T0 to T360 Minutes (6 Hours After Study Drug Administration)
Degrees celsiusIntravenous (IV) PlaceboIntravenous (IV) Acetaminophen 1 g
Maximum Temperature Change During the Period From T0 to T360 Minutes (6 Hours After Study Drug Administration)-0.9 ± 0.75-1.3 ± 0.65
SecondaryThe Percentage of Subjects With Temperature Less Than 38 Degrees Celsius at Any Timepoint During the Time From T0 to T360 Minutes (6 Hours After Study Drug Administration)
Time frame:
360 minutes (6 hours after study drug administration)
Reported as:
Number · Percentage of participants
The Percentage of Subjects With Temperature Less Than 38 Degrees Celsius at Any Timepoint During the Time From T0 to T360 Minutes (6 Hours After Study Drug Administration)
Percentage of participantsIntravenous (IV) PlaceboIntravenous (IV) Acetaminophen 1 g
The Percentage of Subjects With Temperature Less Than 38 Degrees Celsius at Any Timepoint During the Time From T0 to T360 Minutes (6 Hours After Study Drug Administration)313
SecondaryGlobal Assessment of Treatment at T360 Minutes or Early Termination.

Subject Global Evaluation was assessed by subject using a 4 point categorical scale in response to the following question:Overall, how would you rate the study treatments? 0 = Poor 1. = Fair 2. = Good 3. = Excellent

Time frame:
Baseline (T0) to 6 hours
Reported as:
Number · participants
Global Assessment of Treatment at T360 Minutes or Early Termination.
participantsIntravenous (IV) PlaceboIntravenous (IV) Acetaminophen 1 g
Rate treatment as 'poor'21
Rate treatment as 'fair'95
Rate treatment as 'good'1016
Rate treatment as 'excellent'89

Adverse events

Collected over Treatment Emergent Adverse Events(TEAEs)were reported from T0 (on or after the start of study medication) to 6 hours after study medication was administered to the subject.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Intravenous (IV) Placebo—0/29 (0%)13/29 (44.8%)
Intravenous (IV) Acetaminophen 1 g—0/31 (0%)14/31 (45.2%)
Most frequent other events
Showing 10 of 12
Most frequent other events
EventIntravenous (IV) PlaceboIntravenous (IV) Acetaminophen 1 g
Gamma-glutamyltransferase increasedInvestigations8/295/31
Alanine aminotransferase increasedInvestigations6/295/31
Aspartate aminotransferase increasedInvestigations4/296/31
NauseaGastrointestinal disorders4/292/31
DiarrhoeaGastrointestinal disorders3/291/31
VomitingGastrointestinal disorders3/291/31
HeadacheNervous system disorders3/290/31
Blood bilirubin increasedInvestigations1/293/31
DizzinessNervous system disorders2/292/31
Mucosal drynessGeneral disorders2/291/31

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Intravenous (IV) PlaceboIntravenous (IV) Acetaminophen 1 gTotal
<=18 years000
Between 18 and 65 years293160
>=65 years000
Age, Continuous
Age, Continuous(years)Intravenous (IV) PlaceboIntravenous (IV) Acetaminophen 1 gTotal
Mean30.0 ± 10.0229.7 ± 7.3529.9 ± 8.67
Sex: Female, Male
Sex: Female, Male(Participants)Intravenous (IV) PlaceboIntravenous (IV) Acetaminophen 1 gTotal
Female000
Male293160
Region of Enrollment
Region of Enrollment(participants)Intravenous (IV) PlaceboIntravenous (IV) Acetaminophen 1 gTotal
United States293160
08

Study locations

1 site
  • Scirex Research Center
    Austin, Texas 78705, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2007, a primary completion of Oct 2007 and a completion of Oct 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2010, 2 years 11 months after primary completion. A results delay was requested in Apr 2009.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2007
First posted
Jun 28, 2007
Start
Jun 2007
Primary completionActual
Oct 2007
CompletionActual
Oct 2007
Results delay requested
Apr 3, 2009
Results first posted
Sep 21, 2010
Last update
Oct 19, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 19, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00493311
Lead sponsor
Mallinckrodt
Responsible party
Sponsor
First posted
Jun 28, 2007
Start date
Jun 2007
Primary completion
Oct 2007
Completion
Oct 2007
Results posted
Sep 21, 2010
Last update
Oct 19, 2016

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acetaminophen

Start the discussion